A new animal model sheds light on the dark mystery of Alzeheim disease. A molecule called MEG 3 is capable of causing human brain cells to die, making it a potential risk factor for Alzeheimer's disease.
An Australian study found that antibody drugs for Alzheimer's, such as aducanumab and lecanemab, can reduce brain volumes. Despite successful reduction of Alzheimer's-specific amyloid-beta deposits, the benefit of these drugs remains questionable. They slow cognitive decline only slightly and have severe side effects. The study also suggests that these drugs promote the cardinal structural symptom of Alzheimer's disease, brain atrophy. Thus, they increase the risk of brain tissue loss, a direct cause of cognitive decline in Alzheimer's disease.
At regular time intervals, we would like to draw your attention to current reports on the Internet that are closely related to our core topic of lifestyle-oriented and self-responsible prevention and treatment of dementia and its relevance. The opinions expressed there should stimulate a critical exchange of views. They do not necessarily reflect the positions we hold, but in all cases they enrich the basis for discussion. t the end of each press article, we refer to our scientifically based KsD articles - please make up your own mind!
Since 2022 the team of the project "Knowledge stops Dementia" started to refer on a regular base to current contributions from the world wide web which have a close relation to our core topic, the early detection of individual risk factors and thus the lifestyle-oriented and self-responsible prevention and treatment of dementia-related diseases. The opinions expressed in the following articles should serve as a stimulus for critical discussion. They do not necessarily correspond to the positions we hold, but in all cases, they enrich the basis for discussion. Occasionally, we also refer to current freely available studies at the end – please make up your own mind!
The situation is escalating: While the number of Alzheimer's patients in Germany and worldwide is increasing dramatically, a pharmacological [...]
The Amyloid theory is accepted to date as the major justification for the development of Alzheimer's disease and has guided the focus of research in this area. According to this theory, the formation of amyloid plaques, often also referred to as senile plaques, that is, abnormal deposits of the amyloid beta protein (Aβ) in the brain would be the direct cause for the symptoms of this type of dementia. This theory was born in the first description of the disease in 1907, when Alois Alzheimer found a large amount of those plaques distributed in the brain of his famous patient Auguste Deter, when examining her brain after her death. In 1984, Aβ was identified as the main component of the plaques.
Before heading out for the summer break, the team of Knowledge stops Dementia, would like to inform you about an exciting study result, which this time is not about dementia, but about a rarer, but very serious, incurable disease of the central and peripheral nervous system: amyotrophic lateral sclerosis, also known as Lou Gehrig's disease or ALS for short.
Since 2022 the team of the project "Knowledge stops Dementia" started to refer on a regular base to current contributions from the world wide web which have a close relation to our core topic, the early detection of individual risk factors and thus the lifestyle-oriented and self-responsible prevention and treatment of dementia-related diseases. The opinions expressed in the following articles should serve as a stimulus for critical discussion. They do not necessarily correspond to the positions we hold, but in all cases, they enrich the basis for discussion. Occasionally, we also refer to current freely available studies at the end – please make up your own mind!
interesting therapy option, once Alzheimer's disease is the leading cause of dementia in individuals over 65 and has a major negative impact on the lives of patients, relatives and caregivers. Furthermore, it generates a large economic and financial burden for both the patient's family and healthcare systems.
Spermidine, also known chemically as N-(3-aminopropyl) butane-1,4-diamine, is one of the naturally occurring polyamines. It occurs as a natural substance in amino acid metabolism of all living organisms and in all cells, and therefore also in a variety of plant and animal foods. Particularly rich food sources are wheat germ, but hard cheese, dried soybeans and some other foods also provide good amounts of spermidine. Recently, it was shown in mice that spermidine from food actually reaches the brain, thus crossing the blood-brain barrier.
© Copyright by Deutsche Stiftung für Gesundheitsinformation und Prävention | All Rights Reserved
